-
AbbVie Partners with Medincell for Development of Long-Acting Injectable Therapies
•
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has entered into a partnership with France-based biopharmaceutical firm Medincell (EPA: MEDCL) to develop up to six long-acting injectable treatments across multiple therapeutic areas. As per the agreement, Medincell will receive an upfront payment of USD 35 million, with the potential for…
-
Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech
•
GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), achieved sales of USD 157 million for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), in the first quarter of 2024, which…
-
J&J’s Medical Technology Sector Rises 6.3% YOY Despite China’s VBP Impact
•
Johnson & Johnson (J&J; NYSE: JNJ) has reported its financial results for the first quarter of 2024, announcing global sales of USD 21.4 billion, marking a 3.9% year-on-year (YOY) increase in operational terms. Both business segments performed well, with innovative medicines seeing a 2.5% YOY rise to USD 13.6 billion.…
-
China Unveils 2024 Plan to Combat Fraud in Medical Insurance Funds
•
The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court, the Supreme People’s Procuratorate, the Ministry of Public Security, the Ministry of Finance, and the National Health Commission, has unveiled the “2024 Special Work Plan for the Rectification of Illegal and Non-compliant Issues Related to…
-
Chinese Authorities Launch Special Plan to Rectify Medical Insurance Fraud and Non-Compliance
•
The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court, Supreme People’s Procuratorate, Ministry of Public Security, Ministry of Finance, and National Health Commission, has jointly issued the “2024 Special Work Plan for the Rectification of Illegal and Non-compliant Issues Related to Medical Insurance Funds.”…
-
China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation
•
The National Medical Products Administration (NMPA) in China has released the 79th batch of reference drugs for Generic Quality Consistency Evaluation (GQCE) work, marking a significant step in ensuring the quality and consistency of generic drugs in the country. This batch includes 64 new specifications and 34 modified specifications for…
-
AstraZeneca’s Imfinzi Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer Trial
•
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year results from a Phase III clinical trial of its anti-PD-L1 therapy Imfinzi (durvalumab) in combination with chemotherapy for the treatment of advanced biliary tract cancer (BTC). The trial, after a median follow-up of 41.3 months,…
-
China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan
•
The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision Plan Project,” calling for the participation of medical products administration bureaus from key provinces and cities, including Beijing, Tianjin, Liaoning, Shanghai, Jiangsu, Zhejiang, Shandong, Hubei, and Guangdong, as well as Guangzhou city. The National Institutes…
